You are here: Industry Insights > CStone

News List

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST prnasia
December 16, 2019
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone's partner, Blueprint Medicines, has completed target pat
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia prnasia
December 16, 2019
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods Adm
First patient dosed for Phase I/II trial of avapritinib in advanced GIST biospectrumasia
August 26, 2019
CStone announces on a registrational bridging study in China which includes a Phase I dose-escalation study and Phase II dose-expansion study to evaluate safety, pharmacokinetics and efficacy of avapritinib in patients with metastatic gastrointestinal str
CStone registers for Phase I trial of CDK4/6 inhibitor CS3002 in Australia biospectrumasia
August 25, 2019
An open-label, multi-dose, dose-escalation, and dose-expansion Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour efficacy of CS3002 in patients with advanced solid tumours
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting biospectrumasia
August 21, 2019
The CS1001-201 trial reported in the abstract is a single-arm, multi-centre Phase II clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CS1001 monotherapy in relapsed or refractory extranodal natural killer (
CStone to build Global R&D HQ and Industrialization base in China biospectrumasia
August 08, 2019
CStone is committed to the development of innovative oncology treatments
CStone to Build Global R&D Headquarters in Suzhou contractpharma
August 08, 2019
Aims to enhance the company's capabilities and efficiency in R&D and the potential for future collaborations.
CStone announces first patient dosed in China with avapritinib for advanced GIST biospectrumasia
July 10, 2019
Global Phase III clinical trial to evaluate the safety and efficacy of avapritinib as a 3rd or 4th line treatment for patients with gastrointestinal stromal tumours (GIST), in comparison with regorafenib
CStone and Bayer to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib biospectrumasia
June 10, 2019
Combination therapy of PD-1/PD-L1 antibodies with multi-kinase inhibitors that target VEGFR can induce significant synergistic anti-tumour effects, demonstrating CS1001 immuno-oncology potential in patients suffering from gastric cancer and serious malign
CStone submits new drug application for TIBSOVO(R) for treatment of relapsed/refractory AML biospectrumasia
June 03, 2019
First to-be-approved treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible IDH1 mutation

Previous page 1 2 3 4 5 Next page